Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Key Points

  • Biogen's Q4 revenue and profit exceeded expectations, driven by cost cuts and new product growth.
  • The company's 2025 earnings guidance was below Wall Street's expectations, reflecting a foreign exchange headwind.
  • Revenue is expected to decline in 2025 due to falling sales of multiple sclerosis products, offset by growth in new treatments like Leqembi.

Summary

Biogen reported a strong fourth quarter with revenue and profit surpassing expectations, thanks to cost-cutting measures and the growth of new products like Leqembi, their breakthrough Alzheimer’s treatment. Despite this, the company's full-year 2025 earnings outlook disappointed Wall Street, projecting $15.25 to $16.25 per share, below the anticipated $16.34 per share. This lower guidance is attributed to a foreign exchange headwind and an expected mid-single digit percentage decline in revenue for 2025, primarily due to declining sales of multiple sclerosis treatments facing generic competition. However, Biogen anticipates that new treatments like Leqembi, along with drugs for rare diseases and depression, will help mitigate these losses. Leqembi, co-developed with Eisai, has seen a gradual launch due to various logistical challenges but still managed to exceed sales expectations for the quarter. Additionally, Biogen's cost-cutting initiatives are expected to yield significant savings by the end of 2025, and new partnerships and acquisitions, like the funding from Royalty Pharma for litifilimab, are part of their strategy to bolster their pipeline.

cnbc
February 12, 2025
Stocks
Read article

Related news